Key facts
- This page summarizes Joshua Reed's Form 4 filing for Aldeyra Therapeutics, Inc. (ALDX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Apr 2022, 19:37.
Joshua Reed - 30 Mar 2022 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ALDX
- Reported as of
- 30 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2022, 19:37:15 UTC
- Next SEC filing
- 02 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua Reed
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joshua Reed filed Form 4 for Aldeyra Therapeutics, Inc. (ALDX) on 01 Apr 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALDX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +93,322
- Change %
- +51%
- Price
- $0.000000
- Shares after
- 274,825
- Date
- 30 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALDX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +250,000
- Change %
- Price
- $0.000000
- Shares after
- 250,000
- Date
- 30 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $4.52
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
Footnote F2
Includes 8,022 shares previously purchased under the Issuer's Employee Stock Purchase Plan.
Footnote F3
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022.